| 4.68 Data as of 4:00pm ET |  +0.23 / +5.17%Today’s Change | 2.55 Today|||52-Week Range 6.65 | -5.45% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Pharmaceuticals: Other | MARKET CAP $70.3M |
Company Description
Alexza Pharmaceuticals, Inc. is a pharmaceutical company, which is focused on the research, development, and commercialization of novel proprietary products for the acute treatment of central nervous system, or CNS, conditions. The company's product candidates are based on its proprietary technology, the Staccato system. Its lead product candidate is ADASUVE, which is being developed for the acute treatment of agitation in adults with schizophrenia or bipolar disorder. The company's other product candidates, which are in clinical stage includes AZ-007, Staccato nicotine, AZ-10, AZ-002 and AZ-002. Alexza Pharmaceuticals was founded by Dr. Alejandro Zaffaroni on December 19, 2000 and is headquartered in Mountain View, CA.
Employees
Shareholders
| Individual stakeholders | 9.42% |
| Other institutional | 26.09% |
| Mutual fund holders | 11.36% |
Top Executives
| Thomas Braxton King, MBA | President, Chief Executive Officer & Director |
| Michael J. Simms, MBA | Senior Vice President-Operations & Manufacturing |
| Mark K. Oki, CPA | Chief Financial Officer, Secretary, CAO & SVP |
| James V. Cassella, PhD | Chief Scientific Officer |
| Robert S. Fishman, MD | Vice President-Clinical Development |
.
